atorvastatin has been researched along with homocysteine in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (44.83) | 29.6817 |
| 2010's | 13 (44.83) | 24.3611 |
| 2020's | 3 (10.34) | 2.80 |
| Authors | Studies |
|---|---|
| Bruckert, E; Chapman, MJ; Foglietti, MJ; Giral, P; Jacob, N; Turpin, G | 1 |
| Atwal, AS; Davis, M; Hamilton, G; Jagroop, IA; Mikhailidis, DP; Nair, DR; Seifalian, AM | 1 |
| Elisaf, M; Kakafika, A; Tsimihodimos, V | 1 |
| Azuma, A; Harada, S; Kunitomo, K; Kuwahara, N; Nakagawa, M; Sasaki, S; Takeda, K; Yamada, T | 1 |
| Chasiotis, G; Elisaf, M; Miltiadous, G; Papakostas, J; Seferiadis, K | 1 |
| Chasiotis, G; Elisaf, MS; Kakafika, A; Milionis, HJ; Papakostas, J; Seferiadis, K | 1 |
| García-Idoate, G; Mora, C; Muros, M; Navarro, JF | 1 |
| Shah, DI; Singh, M | 1 |
| Bolaman, Z; Kadikoylu, G; Ozgel, N; Yenisey, C | 1 |
| Altug, T; Aslan, M; Balci, H; Bolayirli, IM; Hacibekiroglu, M; Seven, A | 1 |
| Berker, B; Cengiz, SD; Cesur, M; Demirtaş, S; Erdoğan, G; Kaya, C | 1 |
| Boroumand, MA; Djalali, M; Eshragian, MR; Khatami, MR; Shojaei, MH; Siassi, F | 1 |
| Bao, XM; Lu, GP; Wu, CF | 3 |
| Chen, Z; Jia, F; Lu, G; Wu, C | 2 |
| Koppensteiner, R; Spring, S; van der Loo, B | 1 |
| Bao, XM; Zheng, H | 1 |
| Gilowski, W; Krysiak, R; Okopien, B; Szkrobka, W | 1 |
| Broncel, M; Chwatko, G; Jackowska, P; Koter-Michalak, M; Kubalczyk, P; Olszewska-Banaszczyk, M; Pytel, E | 1 |
| Chen, Z; Jia, F; Lu, G; Sun, J; Wu, C | 1 |
| Al-Muzafar, HM; Amin, KA | 1 |
| Bolevich, S; Jakovljevic, V; Joksimovic, J; Katanic, J; Mihailovic, V; Mijailovic, N; Nikolic, T; Pantic, M; Rosic, G; Selakovic, D; Zivkovic, V | 1 |
| Krysiak, R; Okopień, B; Szkróbka, W | 2 |
| Bednarska-Czerwińska, A; Kowalcze, K; Krysiak, R; Okopień, B | 1 |
| Kowalcze, K; Krysiak, R; Okopień, B | 1 |
| Bottiglieri, T; Fardo, DW; Johnson, SN; Qiao, Q; Rogers, CB; Sudduth, TL; Weekman, EM; Wilcock, DM; Xie, K | 1 |
8 trial(s) available for atorvastatin and homocysteine
| Article | Year |
|---|---|
Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia.
Topics: Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Chromatography, High Pressure Liquid; Cysteine; Dipeptides; Female; Fenofibrate; Heptanoic Acids; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Triglycerides | 2001 |
The effect of short-term lipid lowering with atorvastatin on carotid artery intima media thickness in patients with peripheral vascular disease: a pilot study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Carotid Arteries; Cholesterol; Exercise Test; Female; Fibrinogen; Heptanoic Acids; Homocysteine; Humans; Male; Middle Aged; Peripheral Vascular Diseases; Pilot Projects; Pyrroles; Statistics, Nonparametric; Tunica Intima; Tunica Media; Ultrasonography | 2000 |
Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia.
Topics: Analysis of Variance; Atorvastatin; Blood Glucose; Female; Fenofibrate; Heptanoic Acids; Homocysteine; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Simvastatin; Uric Acid | 2003 |
Comparative effects of atorvastatin and simvastatin on the plasma total homocysteine levels in women with polycystic ovary syndrome: a prospective randomized study.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Homocysteine; Humans; Hyperhomocysteinemia; Metabolic Clearance Rate; Polycystic Ovary Syndrome; Pyrroles; Retrospective Studies; Simvastatin; Treatment Outcome | 2009 |
High-dose atorvastatin treatment in patients with peripheral arterial disease: effects on platelet aggregation, blood rheology and plasma homocysteine.
Topics: Aged; Atorvastatin; Female; Hemorheology; Heptanoic Acids; Homocysteine; Humans; Male; Middle Aged; Peripheral Arterial Disease; Platelet Aggregation; Prospective Studies; Pyrroles | 2011 |
The Effect of Atorvastatin on Cardiometabolic Risk Factors in Bromocriptine-Treated Premenopausal Women with Isolated Hypercholesterolemia.
Topics: Adult; Atorvastatin; Bromocriptine; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet; Dopamine Agonists; Exercise; Female; Fibrinogen; Homocysteine; Humans; Hypercholesterolemia; Hyperprolactinemia; Hypoglycemic Agents; Hypolipidemic Agents; Metformin; Middle Aged; Premenopause; Risk Factors; Uric Acid | 2015 |
Intensive statin therapy, used alone or in combination with ezetimibe, improves homocysteine level and lipid peroxidation to a similar degree in patients with coronary artery diseases.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Cholesterol, LDL; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Female; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Male; Middle Aged; Rosuvastatin Calcium | 2016 |
Different Effects of Atorvastatin on Cardiometabolic Risk Factors in Young Women With and Without Hyperprolactinemia.
Topics: Adult; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Female; Fibrinogen; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperprolactinemia; Lipids; Metabolic Diseases; Middle Aged; Prolactin; Risk Factors | 2019 |
21 other study(ies) available for atorvastatin and homocysteine
| Article | Year |
|---|---|
Effect of atorvastatin on serum uric acid levels.
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pyrroles; Uric Acid | 2001 |
Effects of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Electrophoresis, Polyacrylamide Gel; Heptanoic Acids; Homocysteine; Humans; Hyperlipoproteinemias; Lipoprotein(a); Middle Aged; Pyrroles; Triglycerides | 2002 |
Statins and homocysteine.
Topics: Atorvastatin; Heptanoic Acids; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperhomocysteinemia; Pyrroles; Risk Factors; Simvastatin | 2003 |
Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis.
Topics: Adult; Aged; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Homocysteine; Humans; Hypercholesterolemia; Kidney Failure, Chronic; Lipid Metabolism; Lipids; Lipoproteins, LDL; Male; Middle Aged; Oxidative Stress; Prospective Studies; Pyrroles; Renal Dialysis; Risk Factors | 2003 |
Involvement of Rho-kinase in experimental vascular endothelial dysfunction.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acetylcholine; Animals; Antibiotics, Antineoplastic; Aorta, Thoracic; Atorvastatin; Blood Glucose; Diabetes Complications; Diabetes Mellitus, Experimental; Endothelium, Vascular; Heptanoic Acids; Homocysteine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperhomocysteinemia; Intracellular Signaling Peptides and Proteins; Male; Nitrates; Nitrites; Oxidative Stress; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrroles; Rats; Rats, Sprague-Dawley; rho-Associated Kinases; Streptozocin; Thiobarbituric Acid Reactive Substances; Vasodilation | 2006 |
Effects of atorvastatin on coagulation parameters and homocysteine in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Blood Coagulation; Coronary Disease; Female; Fibrinogen; Follow-Up Studies; Heptanoic Acids; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome | 2006 |
Effects of atorvastatin therapy on hypercholesterolemic rabbits with respect to oxidative stress, nitric oxide pathway and homocysteine.
Topics: Animals; Arginine; Aryldialkylphosphatase; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diet; Heptanoic Acids; Homocysteine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Peroxidation; Male; Nitric Oxide; Nitric Oxide Synthase; Oxidative Stress; Pyrroles; Rabbits; Thiobarbituric Acid Reactive Substances; Triglycerides | 2007 |
Serum levels of lipoprotein(a) and homocysteine in patients on hemodialysis who take hydroxymethylglutaryl-CoA reductase inhibitors, vitamin B6, and folic acid.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cross-Sectional Studies; Eating; Female; Folic Acid; Heptanoic Acids; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Lipoprotein(a); Lovastatin; Male; Middle Aged; Pyrroles; Renal Dialysis; Risk Factors; Vitamin B 6; Vitamin B Complex; Young Adult | 2009 |
Atorvastatin attenuates homocysteine-induced apoptosis in human umbilical vein endothelial cells via inhibiting NADPH oxidase-related oxidative stress-triggered p38MAPK signaling.
Topics: Apoptosis; Atorvastatin; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Cells; Endothelium, Vascular; Enzyme Inhibitors; Heptanoic Acids; Homocysteine; Humans; Imidazoles; NADPH Oxidases; Onium Compounds; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyridines; Pyrroles; Reactive Oxygen Species; Signal Transduction; Time Factors; Umbilical Veins | 2009 |
Atorvastatin inhibits homocysteine-induced oxidative stress and apoptosis in endothelial progenitor cells involving Nox4 and p38MAPK.
Topics: Apoptosis; Atorvastatin; Cells, Cultured; Endothelial Cells; Enzyme Activation; Heptanoic Acids; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; NADPH Oxidase 4; NADPH Oxidases; Onium Compounds; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Pyrroles; Reactive Oxygen Species; Stem Cells | 2010 |
Atorvastatin inhibits homocysteine-induced dysfunction and apoptosis in endothelial progenitor cells.
Topics: Animals; Apoptosis; Atorvastatin; Caspase 3; Cells, Cultured; Endothelial Cells; Gene Expression Regulation; Heptanoic Acids; Homocysteine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; NADPH Oxidases; Nitric Oxide; Nitric Oxide Synthase Type III; p38 Mitogen-Activated Protein Kinases; Pyrroles; Reactive Oxygen Species; RNA, Messenger; Stem Cells | 2010 |
AMP-activated protein kinase inhibits homocysteine-induced dysfunction and apoptosis in endothelial progenitor cells.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Apoptosis; Atorvastatin; Cell Movement; Cell Proliferation; Cells, Cultured; Down-Regulation; Endothelial Cells; Heptanoic Acids; Homocysteine; Humans; NADPH Oxidase 4; NADPH Oxidases; Nitric Oxide; Nitric Oxide Synthase Type III; Phosphorylation; Pyrroles; Reactive Oxygen Species; Ribonucleotides; Stem Cells; Up-Regulation | 2011 |
Atorvastatin inhibits homocysteine-induced endoplasmic reticulum stress through activation of AMP-activated protein kinase.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Blotting, Western; Dose-Response Relationship, Drug; Endoplasmic Reticulum Stress; Heptanoic Acids; Homocysteine; Human Umbilical Vein Endothelial Cells; Humans; Lipids; Mice; Polymerase Chain Reaction; Pyrroles; Ribonucleotides; Time Factors | 2012 |
Atorvastatin attenuates homocysteine-induced migration of smooth muscle cells through mevalonate pathway involving reactive oxygen species and p38 MAPK.
Topics: Animals; Atorvastatin; Cell Movement; Dose-Response Relationship, Drug; Homocysteine; MAP Kinase Signaling System; Mevalonic Acid; Myocytes, Smooth Muscle; NADPH Oxidases; p38 Mitogen-Activated Protein Kinases; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species | 2015 |
Atorvastatin attenuates atherosclerotic plaque destabilization by inhibiting endoplasmic reticulum stress in hyperhomocysteinemic mice.
Topics: Animals; Aorta; Apolipoproteins E; Atorvastatin; Blotting, Western; Down-Regulation; Endoplasmic Reticulum Stress; Homocysteine; Hyperhomocysteinemia; Macrophages; Male; Matrix Metalloproteinase 9; Methionine; Mice; Mice, Knockout; Plaque, Atherosclerotic; RAW 264.7 Cells; Real-Time Polymerase Chain Reaction; Thapsigargin; Tumor Necrosis Factor-alpha | 2016 |
Efficacy of functional foods mixture in improving hypercholesterolemia, inflammatory and endothelial dysfunction biomarkers-induced by high cholesterol diet.
Topics: Animals; Atorvastatin; Cholesterol; Creatine Kinase; Diet, High-Fat; Dietary Fats; Drug Administration Schedule; Functional Food; Homocysteine; Hypercholesterolemia; L-Lactate Dehydrogenase; Male; Nitric Oxide Synthase Type III; Rats; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2017 |
The anxiolytic effects of atorvastatin and simvastatin on dietary-induced increase in homocysteine levels in rats.
Topics: Animals; Anti-Anxiety Agents; Anticholesteremic Agents; Anxiety Disorders; Atorvastatin; Behavior, Animal; Diet; Homocysteine; Hyperhomocysteinemia; Lipid Peroxidation; Male; Oxidative Stress; Rats; Rats, Wistar; Simvastatin | 2019 |
The effect of atorvastatin on cardiometabolic risk factors in women with non-classic congenital adrenal hyperplasia: A pilot study.
Topics: Adrenal Hyperplasia, Congenital; Adult; Androgens; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Dehydroepiandrosterone Sulfate; Female; Fibrinogen; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pilot Projects; Risk Factors; Testosterone; Uric Acid; Vitamin D | 2019 |
The impact of atorvastatin on cardiometabolic risk factors in brothers of women with polycystic ovary syndrome.
Topics: Adult; Aged; Androgens; Anticholesteremic Agents; Atorvastatin; Blood Glucose; C-Reactive Protein; Cardiometabolic Risk Factors; Female; Fibrinogen; Homocysteine; Humans; Hydroxycholecalciferols; Insulin Resistance; Lipids; Male; Middle Aged; Polycystic Ovary Syndrome; Risk Factors; Testosterone; Uric Acid | 2021 |
Cabergoline-Induced Hypoprolactinemia May Attenuate Cardiometabolic Effects of Atorvastatin: A Pilot Study.
Topics: Androgens; Atorvastatin; C-Reactive Protein; Cabergoline; Cardiovascular Diseases; Female; Fibrinogen; Homocysteine; Humans; Insulin Resistance; Pilot Projects; Prolactin; Risk Factors; Uric Acid | 2022 |
Atorvastatin rescues hyperhomocysteinemia-induced cognitive deficits and neuroinflammatory gene changes.
Topics: Alzheimer Disease; Animals; Atorvastatin; Cognition; Cognitive Dysfunction; Dementia, Vascular; Homocysteine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperhomocysteinemia; Mice | 2023 |